https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:10716 Sat 24 Mar 2018 08:08:26 AEDT ]]> Side effects and toxicities of targeted therapies in stage IV melanoma https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20976 Sat 24 Mar 2018 07:54:20 AEDT ]]>